Enhancing Child Mental Health Services with Digital Interventions

By Melike Belenli Gümüş

October 8, 2024

Introduction

Child mental health services face significant challenges worldwide, with a clear gap between demand and available care. Digital interventions in child mental health offer promising solutions to bridge this gap, enhancing service capacity without sacrificing quality. A recent article explores the integration of digital interventions, focusing on anxiety disorders, which affect over 25% of individuals throughout their lives. While effective treatments like cognitive behavioural therapy (CBT) exist, access remains limited due to high demand and lengthy wait times.

Cognitive Behavioural Therapy and Digital Augmentation

CBT is a well-established treatment for childhood anxiety disorders. However, only a small fraction of affected children receives evidence-based treatment. Barriers such as high demand on services and long waiting lists necessitate more efficient delivery mechanisms. Brief forms of CBT, particularly those that are parent-led with therapist guidance, have shown effectiveness for pre-adolescent children. This approach not only reduces therapy time but also alleviates stigma and disruption in children’s lives by integrating treatment into daily family activities.

Digital augmentation of parent-led CBT can further enhance accessibility and efficiency. By allowing parents to engage with core treatment content at their convenience, digital platforms provide personalised therapist support. A small trial demonstrated promising results for pre-school children, suggesting that digital interventions could significantly improve treatment access and outcomes.

The Study and Its Findings

The study evaluated a novel, digitally augmented, therapist-supported, parent-led CBT approach known as Online Support and Intervention (OSI). It is a digital tool designed to assist parents in managing child anxiety. It provides structured content through various media, including text, audio, and video. The intervention is divided into seven modules, each focusing on empowering parents to address their child’s anxiety. Therapists support parents through weekly sessions, ensuring the content is tailored to each child’s needs.

A total of 444 children, between the ages of 5 and 12, who primarily experienced anxiety problems, took part in the trial. Results indicated that OSI plus therapist support was non-inferior to traditional treatment methods. It required significantly less therapist contact time, with OSI sessions averaging 182 minutes compared to 307 minutes for usual treatment. Despite the shorter duration, the digital intervention maintained clinical effectiveness.

Cost-Effectiveness of the Intervention

The cost-effectiveness of OSI in child anxiety treatment is highlighted by its impact on quality-adjusted life years (QALYs). The study utilised the Child Anxiety Impact Scale–Parent Report (CAIS-P) to assess how anxiety interferes with a child’s life across academic, social, and family domains. The CAIS-P, with scores ranging from 0 to 75, provided a comprehensive measure of anxiety-related interference. OSI demonstrated a favourable cost per QALY gained, aligning with the willingness-to-pay threshold of £20,000–30,000 per QALY, as per NICE guidelines. This suggests that OSI not only maintains clinical effectiveness but also offers a financially sustainable model for integrating digital interventions into child mental health services.

Figure 1. Forest plot for primary and secondary outcomes.

Implications for Practice

The findings suggest that digitally augmented interventions like OSI can increase the number of children treated for anxiety without compromising outcomes. The intervention was credible to both parents and therapists, though therapists expressed more comfort with traditional methods due to limited training and experience with the digital platform. Parents appreciated the flexibility and user-friendly design of OSI. They could access content at their convenience, making it easier to integrate into daily life. The study’s context during the COVID-19 pandemic highlighted the pragmatic nature of therapist training, suggesting that more comprehensive training could further improve outcomes.

Future Directions

This trial provides compelling evidence for the clinical and economic viability of digitally augmented psychological therapies. Cost-effectiveness of OSI and positive feedback from participants highlights its potential. Future research should explore the optimal level of training for therapists and investigate outcomes across different anxiety subtypes. As digital interventions continue to evolve, they present a significant opportunity to transform child mental health services, drawing on successful digital implementations in other healthcare areas.

Reference url

Recent Posts

Global AIDS Update 2024
     

Global AIDS Update 2024: Progress and Challenges

📊 The **2024 Global AIDS Update** from UNAIDS reveals critical insights on the ongoing HIV epidemic, progress made, and the challenges that lie ahead.

With nearly 40 million people living with HIV worldwide, it’s clear that while we are progressing, much work remains to ensure equitable access to treatment and services. Learn more about the current trends, treatment coverage, and the urgent need for a sustainable response that respects health and human rights.

#SyenzaNews #HIVAIDS #GlobalHealth

obesity early prevention
       

Early Prevention of Obesity: Tackling from Conception

🔍 Discover groundbreaking insights on obesity prevention from the womb! The insight discusses the importance of monitoring and intervening early to combat obesity through the eprObes project. This proactive approach emphasises the critical role of prenatal care and aims to improve health outcomes for future generations.

Read more to find out how addressing obesity from conception can change lives!

#SyenzaNews #ObesityPrevention #PrenatalCare

inavolisib breast cancer treatment
        

FDA Approves Inavolisib Breast Cancer Treatment

🌟 Big news in breast cancer treatment! The FDA has approved inavolisib (Itovebi) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative breast cancer. This innovative therapy offers new hope for patients who have faced recurrence after prior endocrine therapy.

Learn more about the significant trial outcomes and the role of the FoundationOne Liquid CDx companion diagnostic!

#SyenzaNews #BreastCancer #FDAApproval

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.